Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
induced pluripotent stem cell-derived CD8 alpha-beta T cells (glypican-3-targeted)
- Development stage
- Unknown
- Lead developer
- Century Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intraportal
01
Overview
Induced pluripotent stem cell-derived CD8 alpha-beta T cells (glypican-3-targeted) is an investigational cell therapy developed by Century Therapeutics. It consists of CD8αβ T cells differentiated from induced pluripotent stem cells (iPSCs). These cells are engineered to express a T-cell receptor (TCR) targeting glypican-3 (GPC3) peptides presented by HLA-A24 on tumor cells. Additionally, they possess innate killing capabilities mediated by receptors such as Killer cell lectin-like receptor K1 (NKG2D) and CD226 (DNAM1). The cells are further armored with constitutive secretion of Interleukin-15 (IL-15) and Interleukin-21 (IL-21) to enhance their persistence and serial killing activity, and include immune evasion edits to prevent rejection. This therapy is being developed for the treatment of liver cancer and lung cancer, with administration via intravenous or intraportal routes.
- Other names
- CD8 alpha-beta iPSC-derived-T cellsCD-8 alpha-beta iPSC-derived-T cellsCD 8 alpha-beta iPSC-derived-T cells
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on induced pluripotent stem cell-derived CD8 alpha-beta T cells (glypican-3-targeted).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on induced pluripotent stem cell-derived CD8 alpha-beta T cells (glypican-3-targeted).